Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma.

Scientific reports - 10 Sept 2024

Lee Kyeongmi, Cha Honghui, Kim Jaewon, Jang Yeongjun, Son Yelin, Joe Cheol Yong, Kim Jaesang, Kim Jhingook, Lee Se-Hoon, Lee Sanghyuk

Abstract excerpt

Immune checkpoint blockades are actively adopted in diverse cancer types including metastatic melanoma and lung cancer. Despite of durable response in 20-30% of patients, we still lack molecular markers that could predict the patient responses reliably before treatment. Here we present a composite model for predicting anti-PD-1 response based on tumor mutation burden (TMB) and transcriptome sequencing data of 85...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to CTLA-4 Antigen

Share to Gene Expression Regulation, Neoplastic

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 39256604
DOI: 10.1038/s41598-024-72108-5
PMCID: PMC11387489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma.PMID 39256604Read ↗

Bulk and single-cell transcriptome profiling reveal tumor-specific T-based molecular classification, tumor microenvironment infiltration characterization relevant to combination therapies in lung adenocarcinomaSemantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Identification of T-cell exhaustion-related genes and prediction of their immunotherapeutic role in lung adenocarcinomaSemantic proximity Read ↗

A Transcriptomic Meta-Analysis Identifies Differentially Expressed Genes across Different Types of Cancer and Their Association with Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read ↗

Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancerSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.Semantic proximity Read ↗

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapySemantic proximity Read ↗

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.